[go: up one dir, main page]

SV2004000109A - COMBINATION OF MTP INHIBITORS AND INHIBITORS OF HMG-COA REDUCTASA AND ITS USE IN MEDICINES REF.LEA 33846-SV - Google Patents

COMBINATION OF MTP INHIBITORS AND INHIBITORS OF HMG-COA REDUCTASA AND ITS USE IN MEDICINES REF.LEA 33846-SV

Info

Publication number
SV2004000109A
SV2004000109A SV2000000109A SV2000000109A SV2004000109A SV 2004000109 A SV2004000109 A SV 2004000109A SV 2000000109 A SV2000000109 A SV 2000000109A SV 2000000109 A SV2000000109 A SV 2000000109A SV 2004000109 A SV2004000109 A SV 2004000109A
Authority
SV
El Salvador
Prior art keywords
inhibitors
combination
hmg
lea
ref
Prior art date
Application number
SV2000000109A
Other languages
Spanish (es)
Inventor
Rudi Grutzmann
Ulrich Muller
Hilmar Bischoff
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SV2004000109A publication Critical patent/SV2004000109A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION SE REFIERE AL USO DE UNA COMBINACION DE AL MENOS UN INHIBIDOR DE MTP SELECCIONADO (COMPONENTE A) Y UN INHIBIDOR DE HMG-COA REDUCTASA (COMPONENTE B) PARA LA LUCHA CONTRA ENFERMEDADES DEL SISTEMA CARDIOCIRCULATORIO,A MEDICAMENTOS QUE CONTIENEN ESTA COMBINACION Y A SU OBTENCION.THE INVENTION CONCERNS THE USE OF A COMBINATION OF AT LEAST A SELECTED MTP INHIBITOR (COMPONENT A) AND A REDUCED HMG-COA INHIBITOR (COMPONENT B) FOR THE FIGHT AGAINST CARDIOCIRCULATORY SYSTEM DISEASES THAT ARE COMBINED WITH COMBINATIONS OBTAINING.

SV2000000109A 1999-06-25 2000-06-23 COMBINATION OF MTP INHIBITORS AND INHIBITORS OF HMG-COA REDUCTASA AND ITS USE IN MEDICINES REF.LEA 33846-SV SV2004000109A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19929065A DE19929065A1 (en) 1999-06-25 1999-06-25 Synergistic drug combination, especially for treating cardiovascular diseases associated with metabolic disorders, comprising bi- or tricyclic aza-heterocyclic MTP inhibitor and HMG-CoA reductase inhibitor

Publications (1)

Publication Number Publication Date
SV2004000109A true SV2004000109A (en) 2004-05-07

Family

ID=7912459

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2000000109A SV2004000109A (en) 1999-06-25 2000-06-23 COMBINATION OF MTP INHIBITORS AND INHIBITORS OF HMG-COA REDUCTASA AND ITS USE IN MEDICINES REF.LEA 33846-SV

Country Status (12)

Country Link
EP (1) EP1196194A2 (en)
JP (1) JP2003503342A (en)
AR (1) AR028996A1 (en)
AU (1) AU5680900A (en)
CA (1) CA2376881A1 (en)
DE (1) DE19929065A1 (en)
DO (1) DOP2000000022A (en)
GT (1) GT200000099A (en)
PE (1) PE20010302A1 (en)
SV (1) SV2004000109A (en)
UY (1) UY26218A1 (en)
WO (1) WO2001000183A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10030375A1 (en) * 2000-06-21 2002-01-03 Bayer Ag Use of MTP inhibitors to lower ppTRL
RU2293721C2 (en) * 2002-02-28 2007-02-20 Джапан Тобакко Инк. Ester compounds and their using in medicine
WO2005021486A1 (en) 2003-08-29 2005-03-10 Japan Tobacco Inc. Ester derivative and medicinal use thereof
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
FR2884831B1 (en) * 2005-04-22 2007-08-10 Merck Sante Soc Par Actions Si METHOD FOR SCREENING MTP INHIBITORY COMPOUNDS
DE102011007272A1 (en) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Branched 3-phenylpropionic acid derivatives and their use
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
CN109053927A (en) * 2018-08-08 2018-12-21 中山大学 A kind of amphipathic sodium alginate derivative of the group containing vitamin B12 and its preparation method and application

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4435477A1 (en) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indole and -azaindole derivatives
DE19546918A1 (en) * 1995-12-15 1997-06-19 Bayer Ag Bicyclic heterocycles
DE19546919A1 (en) * 1995-12-15 1997-06-19 Bayer Ag N-heterocyclically substituted phenylacetic acid derivatives
DE19615265A1 (en) * 1996-04-18 1997-12-04 Bayer Ag New pyridazino, pyrimido, pyrazino and triazinoindoles
EP0944602A1 (en) * 1996-11-27 1999-09-29 Pfizer Inc. Apo b-secretion/mtp inhibitory amides
EP1024804A4 (en) * 1997-05-01 2001-03-21 Bristol Myers Squibb Co Mtp inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels

Also Published As

Publication number Publication date
AR028996A1 (en) 2003-06-04
DE19929065A1 (en) 2000-12-28
EP1196194A2 (en) 2002-04-17
PE20010302A1 (en) 2001-04-12
WO2001000183A2 (en) 2001-01-04
WO2001000183A3 (en) 2001-05-10
AU5680900A (en) 2001-01-31
CA2376881A1 (en) 2001-01-04
GT200000099A (en) 2001-12-13
DOP2000000022A (en) 2008-08-15
UY26218A1 (en) 2001-01-31
JP2003503342A (en) 2003-01-28

Similar Documents

Publication Publication Date Title
PA8493401A1 (en) USE OF CYP2D6 INHIBITORS IN COMBINATION THERAPIES
DOP2000000022A (en) COMBINATION OF MTP INHIBITORS AND INHIBITORS OF HMG-COA REDUCTASA AND ITS USE IN MEDICINES.
AR045179A1 (en) USE OF A COMBINATION OF AN INHIBITOR OF THE KINASA OF THE RECEIVER OF THE EPIDERMAL GROWTH FACTOR AND OF CYTOTOXIC AGENTS FOR THE TREATMENT AND INHIBITION OF CANCER
PA8506101A1 (en) USE OF AN ACAT COMPOUND TO MANUFACTURE A PHARMACEUTICAL COMPOSITION
HN2002000150A (en) ANTIBACTERIAL AGENTS
CR7942A (en) ANTHINEOPLASTIC COMBINATIONS UNDERSTANDING A RAPAMYCIN DERIVATIVE AND AN AROMATASE INHIBITOR
PT1328269E (en) ASSOCIATE OF AN ANTAGONIST OF THE CB1 RECEPTOR AND SIBUTRAMINE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES FOR THE TREATMENT OF OBESITY
HN2001000146A (en) PIRAZOL DERIVATIVES
DOP2006000050A (en) A SOLID FORMULATION OF PHARMACEUTICAL DOSAGE
GT200000158A (en) PIRIDINES AND REPLACED PYRIDACINES WITH ANGIOGENESIS INHIBITION ACTIVITY.
AR028959A1 (en) USE OF RAPAMYCIN FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO TREAT CARDIOVASCULAR DISEASES
ECSP044981A (en) OPHTHALMIC COMPOSITION THAT INCLUDES ASCOMYCIN
CL2007000355A1 (en) A combination comprising a cyclin-dependent kinase inhibitor, an antibody that inhibits a growth factor and an antifungal agent; pharmaceutical composition that includes it; and its use to treat a proliferative disorder.
CL2004000366A1 (en) USE OF A COMBINATION OF A QUINASA P38 INHIBITING DERIVED COMPOUND OF PIRAZOL, AND AN ACE INHIBITOR TO TREAT RENAL DYSFUNCTION, CARDIOVASCULAR AND VASCULAR DISEASE, RETINOPATHY, NEUROPATIA, EDOTEL, INSOTUNATIO OPINION.
GT200000077A (en) MUTUAL SALT OF AMLODIPINO AND ATORVASTATINA
BR0002953A (en) Compositions and treatment for diabetic complications
AR030140A1 (en) COMPOSITIONS DERIVED FROM 2-PYRIDINAMINE AND RELATED METHODS
HN2003000071A (en) COMBINATIONS OF A BINDING ALFA-2-DELTA WITH A SELECTIVE INHIBITOR OF THE CYCLOOXYGENASA-2
DK0991424T3 (en) Pharmaceutical compositions comprising an aldose reductase inhibitor and an ACE inhibitor
ES2132539T3 (en) SYNERGIC INSECTICIDE COMPOSITIONS.
MX2008001597A (en) Novel formulations comprising fenofibrate and a statin, and related methods of treatment.
ES2196559T3 (en) FARNESIL TRANSFERASA INHIBITORS IN COMBINATION WITH HMG COA REDUCTASA INHIBITORS FOR CANCER TREATMENT.
BR0002957A (en) Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
GT200200244A (en) INTENSIVE HERBICIDE COMPOSITION
DK1177191T3 (en) Substituted benzimidazoles, preparation and use thereof as agents for the control of parasitic protozoa